ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

formoterol

Also written as “Formoterol Fumarate”, “budesonide/formoterol” and “Formoterol”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Bronchitis, Chronic · Asthma, Exercise-Induced, led by 18 companies.

Drug pageFormoterol: every studyMany companies study it; this page follows only the 137 they lead. All 190 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 4, 2006137 company-led studies, 2 open or runningNext primary completion: May 31, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca632 open or runningphase 4since Jan 4, 2006Sep 13, 2005May 31, 2027phase 4 · NCT07073950
Chiesi Farmaceuticiits history only200 open or runningphase 4since Nov 29, 2010Oct 30, 2006none ahead
Viatrisits history only160 open or runningphase 4since Nov 29, 2011Sep 13, 2005none ahead
Novartisits history only60 open or runningphase 4since Jul 26, 2005Jul 26, 2005none ahead
Sumitomo Pharmaits history only60 open or runningphase 4since Jan 17, 2007Jul 8, 2003none ahead
SkyePharmaits history only50 open or runningphase 3since Oct 27, 2006Oct 27, 2006none ahead
Eurofarma Laboratoriosits history only30 open or runningphase 3since Oct 23, 2009Oct 23, 2009none ahead
Mundipharmaits history only30 open or runningphase 4since Jun 15, 2015Oct 14, 2009none ahead
Ache Laboratorios Farmaceuticosits history only20 open or runningphase 3since Mar 9, 2011Mar 9, 2011none ahead
Boehringer Ingelheimits history only20 open or runningphase 2since Sep 11, 2014Sep 11, 2014none ahead

Also a collaborator on its studies: Parexel, CISCRP, eResearchTechnology, Menarini Group, Integrated Therapeutics Group and Pacira BioSciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 44 studies since Oct 12, 2005.

  1. Feb 17, 2016Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT03262012 · 416 enrolled · Japan
  2. May 6, 20162 phase 3 studies in Pulmonary Disease, Chronic ObstructiveNCT02766608, NCT02796677
  3. Jun 7, 2016Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT02796651 · 132 enrolled · United States
  4. Jan 13, 2017Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT03022097 · 1,625 enrolled · China, India, Philippines and more
  5. Apr 26, 2017Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT03181880
  6. May 19, 2017Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT03162055 · 1,119 enrolled · United States, Bulgaria, Canada and more
  7. Sep 24, 2018Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT03836677 · 23 enrolled · Belgium, Netherlands
  8. Oct 26, 20202 phase 3 studies in AsthmaNCT04609904, NCT04609878
  9. Jan 10, 2022Phase 3 study in AsthmaNCT05202262 · 645 enrolled · United States, Canada, Germany and more
  10. Feb 23, 2023Phase 3 study in AsthmaNCT05755906 · 374 enrolled · United States, Canada, Czechia and more
  11. Sep 28, 2023Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT06067828 · 171 enrolled · United States, Canada, China and more
  12. Feb 21, 2024Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT06283966 · 5,250 planned · United States, Argentina, Australia and more
  13. Jul 17, 2025Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT07073950 · 56 planned · Germany, United Kingdom
  14. Feb 20, 2026Phase 1 study in AsthmaNCT07433569 · 16 enrolled · United States

Ahead

  1. May 31, 2027Primary completion: phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT07073950
  2. Dec 3, 2027Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT06283966

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The newest 60 of 63 AstraZeneca leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT07433569Asthma · United States1CompletedJun 26, 202616
NCT07073950Pulmonary Disease, Chronic Obstructive · Germany, United Kingdom4RecruitingMay 31, 202756
NCT06283966Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3RecruitingDec 3, 20275,250
NCT06067828Pulmonary Disease, Chronic Obstructive · United States, Canada, China and more3CompletedJan 22, 2026171
NCT05755906Asthma · United States, Canada, Czechia and more3CompletedNov 19, 2024374
NCT05202262Asthma · United States, Canada, Germany and more3CompletedFeb 26, 2025645
NCT04609904Asthma · United States, Brazil, China and more3CompletedMar 20, 20252,187
NCT04609878Asthma · United States, Argentina, Belgium and more3CompletedMar 21, 20252,274
NCT03836677Pulmonary Disease, Chronic Obstructive · Belgium, Netherlands3CompletedNov 11, 201923
NCT03162055Pulmonary Disease, Chronic Obstructive · United States, Bulgaria, Canada and more3CompletedMay 4, 20181,119
NCT03181880Pulmonary Disease, Chronic Obstructive4WithdrawnDec 3, 20180
NCT03022097Pulmonary Disease, Chronic Obstructive · China, India, Philippines and more3CompletedApr 14, 20221,625
NCT02796651Pulmonary Disease, Chronic Obstructive · United States2CompletedDec 7, 2016132
NCT02796677Pulmonary Disease, Chronic Obstructive · United States, Bulgaria, Czechia and more3CompletedJun 8, 20171,595
NCT02766608Pulmonary Disease, Chronic Obstructive · United States, Canada, Czechia and more3CompletedDec 1, 20172,389
NCT03262012Pulmonary Disease, Chronic Obstructive · Japan3CompletedJun 15, 2018416
NCT02685293Pulmonary Disease, Chronic Obstructive · United States3TerminatedJun 6, 20184
NCT02536508Pulmonary Disease, Chronic Obstructive · United States3CompletedSep 12, 2017627
NCT02497001Pulmonary Disease, Chronic Obstructive · United States, Canada, China and more3CompletedJan 5, 20181,902
NCT02465567Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3CompletedJul 26, 20198,588
NCT02424344Pulmonary Disease, Chronic Obstructive · Canada, Germany, Hungary and more4CompletedJul 25, 2016267
NCT02347085Pulmonary Disease, Chronic Obstructive3CompletedJun 1, 201543
NCT02347072Pulmonary Disease, Chronic Obstructive3CompletedAug 1, 201580
NCT02343458Pulmonary Disease, Chronic Obstructive · United States, China, Czechia and more3CompletedAug 31, 20171,756
NCT02196714Pulmonary Disease, Chronic Obstructive · United States1CompletedSep 201424
NCT02196077Pulmonary Disease, Chronic Obstructive · United States2CompletedMar 1, 2015180
NCT02189304Pulmonary Disease, Chronic Obstructive · United States1CompletedSep 1, 201459
NCT01908140Pulmonary Disease, Chronic Obstructive · Austria, Bulgaria, Canada and more3CompletedAug 2014933
NCT01854658Pulmonary Disease, Chronic Obstructive · United States3CompletedMar 20151,615
NCT01641081Asthma · United States2CompletedFeb 2013174
NCT01551888Pulmonary Disease, Chronic Obstructive · United States2CompletedMar 201224
NCT01349868Pulmonary Disease, Chronic Obstructive · United States2CompletedJul 201150
NCT01257048Pulmonary Disease, Chronic Obstructive · Sweden, United KingdomEarly 1CompletedJun 201234
NCT01048333Pulmonary Disease, Chronic Obstructive · Italy, Spain, Sweden2CompletedMay 2010109
NCT01047553Pulmonary Disease, Chronic Obstructive · Japan3CompletedJan 2011251
NCT00989833Asthma, Exercise-Induced · Norway, Sweden2CompletedJul 201066
NCT00658255Stable Asthma2Completed175
NCT00652392Asthma3Completed750
NCT00652002Asthma3Completed450
NCT00651768Asthma3Completed570
NCT00651651Asthma3Completed450
NCT00651547Asthma3Completed405
NCT00646009Asthma3Completed48
NCT00628862Pulmonary Disease, Chronic Obstructive · Bulgaria, Japan, Romania and more3CompletedApr 2009613
NCT00536913Asthma · Hungary, Poland, Russian Federation3CompletedFeb 2008107
NCT00489853Pulmonary Disease, Chronic Obstructive · Germany, Switzerland4CompletedAug 2008137
NCT00463866Asthma · Belgium, Finland, France and more4Completed8,424
NCT00419744Pulmonary Disease, Chronic Obstructive · United States, Argentina, Brazil and more3CompletedAug 20091,200
NCT00326053Asthma · Canada3Completed600
NCT00319306Asthma · United Kingdom3Completed550
NCT00290264Asthma · Belgium, Luxembourg3Completed1,000
NCT00288379Asthma · Sweden3Completed16
NCT00272753Asthma · Netherlands4Completed20
NCT00259792Asthma · France3Completed1,000
NCT00259779Pulmonary Disease, Chronic Obstructive · Denmark, Finland, Germany and more3Completed120
NCT00255255Asthma · Japan3CompletedDec 2006120
NCT00252785Asthma · Japan3Completed340
NCT00244608Asthma · Denmark, France, Germany and more3Completed100
NCT00242775Asthma · Argentina, Australia, Brazil and more3Completed2,100
NCT00238784Asthma · Canada3CompletedOct 20051,300

How it is read

Names in the registry

  • “Formoterol Fumarate”, 14 entries
  • “budesonide/formoterol”, 10 entries
  • “Formoterol”, 9 entries
  • “Fluticasone Propionate/Formoterol Fumarate”, 9 entries
  • “BGF MDI 320/14.4/9.6 μg”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.